Targeted Pulse Quiz: October 13

Cologuard Plus test receives FDA approval, understanding genomic profiling leads to advanced personalized care in breast cancer, and a new CAR T therapy is making waves in multiple myeloma.

In this episode of Targeted Talks, Virginia Kaklamani, MD, DSc, discusses the background, findings, and implications of the phase 3 EMERALD trial.

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

During a Case-Based Roundtable® event, Sagar D. Sardesai, MD, moderated a discussion on using antibody-drug conjugates and managing their toxicities in patients with metastatic breast cancer.

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.